How To Use HCPCS Code C1717

HCPCS code C1717 describes a brachytherapy source, specifically a non-stranded, high dose rate iridium-192 source. This code is used to identify and bill for the use of this specific brachytherapy source in medical procedures. In this article, we will explore the details of HCPCS code C1717, including its official description, procedure, when to use it, billing guidelines, historical information, Medicare and insurance coverage, and provide examples of when this code should be billed.

1. What is HCPCS C1717?

HCPCS code C1717 is used to identify a specific type of brachytherapy source, which is a non-stranded, high dose rate iridium-192 source. Brachytherapy is a form of radiation therapy where a radioactive source is placed directly into or near the tumor site to deliver targeted radiation treatment. This code specifically refers to the use of the iridium-192 source in brachytherapy procedures.

2. Official Description

The official description of HCPCS code C1717 is “Brachytherapy source, non-stranded, high dose rate iridium-192, per source.” The short description for this code is “Enteral supp not otherwise c.” This description accurately represents the specific brachytherapy source being identified by this code.

3. Procedure

1. The provider begins the procedure by preparing the patient for brachytherapy treatment.
2. The non-stranded, high dose rate iridium-192 source is inserted into or near the tumor site using specialized brachytherapy applicators.
3. The source is left in place for a specific amount of time to deliver the prescribed radiation dose.
4. After the treatment period, the source is removed from the patient.
5. The patient is monitored for any potential side effects or complications following the procedure.

4. When to use HCPCS code C1717

HCPCS code C1717 should be used when billing for brachytherapy procedures that utilize a non-stranded, high dose rate iridium-192 source. It is important to ensure that the specific source being used matches the description provided by this code. This code should only be used in the context of brachytherapy treatments and not for other types of procedures or supplies.

5. Billing Guidelines and Documentation Requirements

When billing for HCPCS code C1717, healthcare providers should ensure that the necessary documentation is in place to support the use of this specific brachytherapy source. This may include documentation of the treatment plan, the specific source used, the duration of the treatment, and any other relevant details. Providers should follow the billing guidelines set forth by the payer, ensuring that all required information is included on the claim form.

6. Historical Information and Code Maintenance

HCPCS code C1717 was added to the Healthcare Common Procedure Coding System on January 01, 1985. It has an effective date of January 01, 1996. There have been no maintenance actions taken for this code, as indicated by the action code N, which means no maintenance for this code. This code has remained unchanged since its addition to the HCPCS.

7. Medicare and Insurance Coverage

HCPCS code C1717 is eligible for coverage by Medicare and other insurance providers. The pricing indicator code for this code is 57, which indicates that it is priced by carriers using other methodologies. The multiple pricing indicator code for this code is A, which means it is not applicable as HCPCS priced under one methodology. Providers should refer to the Medicare Carriers Manual Reference Section Number 2130 for specific guidance on billing and reimbursement for this code.

8. Examples

Here are five examples of when HCPCS code C1717 should be billed:

1. A patient with prostate cancer undergoes brachytherapy treatment using a non-stranded, high dose rate iridium-192 source.
2. A patient with cervical cancer receives brachytherapy treatment with the insertion of a non-stranded, high dose rate iridium-192 source.
3. A patient with skin cancer undergoes brachytherapy treatment using a non-stranded, high dose rate iridium-192 source.
4. A patient with breast cancer receives brachytherapy treatment with the placement of a non-stranded, high dose rate iridium-192 source.
5. A patient with lung cancer undergoes brachytherapy treatment using a non-stranded, high dose rate iridium-192 source.